STOCK TITAN

Oculis Publishes Invitation to the Annual General Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Oculis Holding AG has published an invitation to its 2024 Annual General Meeting to be held on May 29, 2024, in Zug, Switzerland. The meeting details and materials are available on the company's website.

Oculis Holding AG ha pubblicato un invito per la sua Assemblea Generale Annuale del 2024, che si terrà il 29 maggio 2024 a Zug, Svizzera. I dettagli e i materiali dell'incontro sono disponibili sul sito web della società.
Oculis Holding AG ha publicado una invitación a su Asamblea General Anual de 2024, que se celebrará el 29 de mayo de 2024 en Zug, Suiza. Los detalles de la reunión y los materiales están disponibles en el sitio web de la empresa.
Oculis Holding AG가 2024년 5월 29일 스위스 주크에서 개최될 2024년 연례 주주총회 초청장을 발표했습니다. 회의 세부사항 및 자료는 회사 웹사이트에서 확인할 수 있습니다.
Oculis Holding AG a publié une invitation à son Assemblée Générale Annuelle 2024 qui se tiendra le 29 mai 2024 à Zug, en Suisse. Les détails de la réunion et les documents sont disponibles sur le site internet de la société.
Oculis Holding AG hat eine Einladung zu ihrer Jahresgeneralversammlung 2024 veröffentlicht, die am 29. Mai 2024 in Zug, Schweiz, stattfinden wird. Die Details der Versammlung und die Materialien sind auf der Website des Unternehmens verfügbar.
Positive
  • None.
Negative
  • None.

ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT.

All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com‌/events-presentations.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577

 


FAQ

When will the 2024 Annual General Meeting of Oculis be held?

The meeting will take place on May 29, 2024.

Where will the meeting be held?

The meeting will be held at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland.

What time will the meeting start?

The meeting will begin at 3:30 p.m. CEST / 9:30 a.m. EDT.

Where can I access the meeting materials?

All information and materials regarding the meeting can be found on the Oculis website at https://investors.oculis.com/events-presentations.

Oculis Holding AG

NASDAQ:OCS

OCS Rankings

OCS Latest News

OCS Stock Data

498.55M
26.50M
7.24%
32.96%
0.09%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Zug